Nkarta to Participate in Needham Virtual Healthcare Conference
Thursday, April 9, 2026 1 min read
Key Takeaway: Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will provide updates on their investigational CAR-NK cell therapy. The event will be accessible via webcast.
Price reaction · baseline $2.31 (2026-04-08 close) · hit after-hours · clean, no other NKTX news in the window
day 0 close
+1.3%
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is participating in a prominent healthcare conference.
CEO and President will share insights on innovative therapies.
The company is advancing its CAR-NK cell therapy for autoimmune diseases.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.
At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, “Cell Therapy in Autoimmune: State of the Art and What Comes Next.”
Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases.A simultaneous webcast of the fireside chat will be available on theInvestors sectionof Nkarta’s website, and a replay will be archived on the website for approximately 90 days.About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website atwww.nkartatx.com.